Search the Newsreel

PolyPid (PYPD) FDA Approvals, PDUFA Dates & Drug Alerts 2026

This article provides a detailed timeline of PolyPid's (PYPD) FDA-related milestones for its drug D-PLEX100, intended to prevent surgical site infections in colorectal surgery. Key events include the FDA's acceptance of the New Drug Application (NDA) with

PLRZ.O PE Ratio & Valuation, Is PLRZ.O Overvalued

This article analyzes the valuation of Polyrizon Ltd (PLRZ.O) using various financial metrics. It states that PLRZ.O is currently in the "Fair zone" based on its forward PS ratio, with a P/B ratio of 1.12 and a Forward FCF yield of -17.34%. The article …

PolyPid stock jumps as FDA accepts D-PLEX100 NDA with priority review

PolyPid Ltd. (NASDAQ:PYPD) shares jumped over 11% after the FDA accepted its New Drug Application for D-PLEX100, granting it priority review for preventing surgical site infections in abdominal colorectal surgery. The FDA set a PDUFA target action date of November 28, 2026, which is …

FDA Acceptance Triggers $15M Payment to PolyPid Under Partnership

PolyPid Ltd. announced that the U.S. FDA has accepted its New Drug Application (NDA) for D-PLEX₁₀₀ with Priority Review, setting a PDUFA target action date of November 28, 2026. This acceptance triggers a $15 million milestone payment from Azurity Pharmaceuticals, completing $30 million in …

PolyPid (Nasdaq: PYPD) gets FDA Priority Review and $15M milestone

PolyPid Ltd. announced that the FDA has granted Priority Review for its New Drug Application (NDA) for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgery, with a PDUFA target action date of November 28, 2026. This acceptance triggers a $15 million …

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PolyPid Ltd. announced that the FDA has accepted its New Drug Application (NDA) for D-PLEX₁₀₀ with Priority Review for the prevention of surgical site infections in abdominal colorectal surgery. The FDA set a PDUFA target action date of November 28, 2026, which is sooner …

PolyNovo (ASX:PNV) Posts Record $150m FY26 Revenue

United Polyfab promoters confirm no new share encumbrances in FY26

Jindal Poly Investment and Finance Co. Ltd. Revenue Breakdown – NSE:JPOLYINVST

PolyPid Ltd. Revenue Breakdown – NASDAQ:PYPD

This page from TradingView provides financial information for PolyPid Ltd. (NASDAQ: PYPD), including an overview of its financials, statements, statistics, dividends, earnings, and segment breakdown. It notes that the market is currently closed with no trades.

PolyPid Ltd (PYPD) Balance Sheet

This article provides a detailed balance sheet for PolyPid Ltd (PYPD), presenting quarterly and annual financial data dating back to 2013. It includes key financial metrics such as assets, liabilities, and shareholders' equity, allowing users to evaluate the company's financial health, liquidity, and leverage. …

Polyrizon Ltd (PLRZ) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Polyrizon Ltd (PLRZ), focusing on its P/E and P/B ratios and fair value. It notes that relevant data for P/E has not yet been disclosed by the company. The stock is currently trading at $12.750, down 9.19%.

Polyrizon Ltd (PLRZ) Cash Flow

This article provides an overview of Polyrizon Ltd's (PLRZ) cash flow statements, including operating, investing, and financing cash flows, along with free cash flow data. It highlights key financial figures such as a -4.53M operating cash flow in fiscal 2025 and an increase of …

Polyrizon Ltd (PLRZ) Institutional Confidence

The article provides a snapshot of Polyrizon Ltd (PLRZ) stock performance, showing a 5.99% drop with a closing price of $13.800. It highlights "Institutional Confidence" as one of the analysis dimensions on the TradingKey platform, listing Izraeli (Tomer) as a significant shareholder with 8.00 …

PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for PolyPid Ltd (PYPD), focusing on volatility, financial risk, and investment risk. It presents various financial metrics including Beta, VaR, Maximum Drawdown, Volatility, and Sharpe Ratio over different time periods. The data indicates the stock's historical performance …

Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Polyrizon Ltd (PLRZ). It states that no dividends have been distributed over the past five years and notes a merger event scheduled for May 22, 2025, with a 250→1 ratio.

PolyPid Ltd (PYPD) Institutional Confidence

This article provides a brief overview of institutional confidence in PolyPid Ltd (PYPD), highlighting key institutional shareholders and their recent activity. It lists the number of shares held by major investors like Aurum Ventures M.K.I., Hodges (Rodney), Centaurus Investments Limited, and AIGH Capital Management, …

Polyrizon Ltd (PLRZ) Balance Sheet

This article provides the balance sheet for Polyrizon Ltd (PLRZ), offering both annual and quarterly financial data to assess the company's financial health. It details key metrics such as cash, assets, liabilities, and shareholders' equity over several fiscal periods, along with FAQs explaining important …

Polymetals Resources Exchanges AU$28 Million Endeavor Mine Rehabilitation Bond; Shares Down 3%

Polyplex re-appoints Sanjay Gupta & Associates as cost auditor

PolyPid, Azurity Sign US$330M Deal for D-PLEX100

PolyPid Ltd. and Azurity Pharmaceuticals have signed an exclusive deal worth up to US$330 million for the commercialization of D-PLEX100, an infection-prevention drug, in the U.S. and Canada. The agreement includes an upfront payment of US$15 million, potential milestone payments, and Azurity funding further …

TradingKey

This article provides an income statement overview for Polyrizon Ltd (PLRZ) on TradingKey, detailing both quarterly and annual financial performance. It explains how to interpret the income statement, highlights the difference between quarterly and annual data, defines 'YOY,' and lists key metrics for analyzing …

Polyrizon Ltd (PLRZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Polyrizon Ltd (PLRZ) using various indicators and moving averages. It details current buy, sell, and neutral signals for indicators like MACD, RSI, and KDJ, with a majority of moving averages (MA5 to MA200) showing buy signals. The …

PLRZ|Polyrizon Ltd|Price:13.800|Chg%:-0.880

This article provides an analysis of Polyrizon Ltd (PLRZ) through TradingKey's stock scoring system, although no score is available due to insufficient data. It details the methodology behind TradingKey's comprehensive stock assessment, explaining how financial health, valuation, earnings forecasts, price momentum, institutional confidence, and …

PYPD|PolyPid Ltd|Price:3.900|Chg%:-0.340

PolyPid Ltd (PYPD) stock closed at $3.900, down 8.02% from its previous close. Analysts currently rate PYPD as a "Buy" with a target price of $12.00, suggesting a significant upside. The company is a biopharmaceutical firm focused on developing locally administered therapies for surgical …

Vardhman Jain Tijaria raises stake in Tijaria Polypipes to 4.33%

Gulshan Polyols confirms no UPSI shared in NDTV media interaction

Polygon Real Estate Ltd. Revenue Breakdown – TASE:POLY

PolyNovo (ASX:PNV) Plunges as Healthcare Stocks Join the Market Retreat

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

PolyPid Ltd. (PYPD:NASDAQ) has entered into a commercialization agreement with Azurity Pharmaceuticals for its antibacterial drug, D-PLEX100, which aims to prevent surgical site infections. The deal provides PolyPid with an upfront payment of US$15 million, potential milestone payments up to US$300 million, and a …

H.C. Wainwright Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $13

H.C. Wainwright has reaffirmed its Buy rating for PolyPid (PYPD.US) and maintained its target price of $13. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

PolyNovo FY26 earnings: Record revenue and cash flow

HC Wainwright Has Optimistic Outlook of PolyPid Q2 Earnings

Polynovo (ASX:PNV) Slides Lower: Medtech Name Pulls Back Despite Broader Gains

H.C. Wainwright reiterates Buy on PolyPid stock, $13 target By Investing.com

H.C. Wainwright has reiterated its Buy rating and $13 price target for PolyPid (NASDAQ:PYPD) following a significant licensing agreement. PolyPid entered an exclusive licensing and collaboration agreement with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada, which includes $30 million upfront/near-term and potential …

Nahar Poly Films Share Price Forecast: 3 Year Outlook to 2030